120
Participants
Start Date
January 1, 2020
Primary Completion Date
June 30, 2020
Study Completion Date
September 30, 2020
TQ-F3083 capsule 10 mg
Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
TQ-F3083 capsule 20 mg
Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
TQ-F3083 blank analog capsule
Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
TQ-F3083 blank analog capsule
Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
Linagliptin blank analog tablet
Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
Linagliptin tablet
Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
NOT_YET_RECRUITING
Yuncheng Central Hospital, Jinan
NOT_YET_RECRUITING
The Second Affiliated Hospital of Chongqing Medical Uversity, Chongqing
NOT_YET_RECRUITING
Chongqing General Hospital, UCAS, Chongqing
NOT_YET_RECRUITING
Xiangya Hospital Central South University, Changsha
NOT_YET_RECRUITING
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
The First People's Hospital of Yunnan Province, Kunming
NOT_YET_RECRUITING
Jincheng Geberal Hospital, Jincheng
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY